Poseida’s Solid Tumor CAR-T Shows Early Promise, But Safety Will Be Closely Watched

Promising Signs In Prostate Cancer

 
• By Andrew McConaghie
  
Poseida
Poseida Therapeutics went public in July 2020, but its stock has sunk since then because of CAR-T safety concerns and promise of competing pipeline cancer modalities.

More from Business

More from Scrip